Recursion Acquires Cyclica and Valence to Bolster Digital Chemistry and Generative AI
May 8, 2023
Recursion (NASDAQ: RXRX) entered into agreements to acquire two AI-enabled drug discovery companies, Cyclica (Toronto) and Valence (Montréal), for aggregate reported purchase prices of $40.0 million and $47.5 million respectively, payable primarily in Recursion equity and exchangeable subsidiary shares. The acquisitions add digital-chemistry, proteome-wide prediction and low-data generative chemistry capabilities to Recursion's RecursionOS and research organization to accelerate its AI-first drug discovery platform.
- Buyers
- Recursion
- Targets
- Cyclica, Valence
- Industry
- Biotechnology
- Location
- Canada
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
MajorKey Technologies Acquires Valence Group, Inc.
December 9, 2021
IT Services
MajorKey Technologies, backed by The Acacia Group, has acquired Seattle-based Valence Group, Inc., a digital transformation consultancy of ~90 consultants and engineers. The add-on strengthens MajorKey's strategic consulting, user-centered design and AI/ML/data-integration capabilities and expands its team to over 650 people.
-
Recipharm AB Acquires Vibalogics from Ampersand Capital Partners
February 18, 2022
Biotechnology
Recipharm AB, a global CDMO based in Sweden, has agreed to acquire Vibalogics, a virotherapy-focused CDMO and Ampersand Capital Partners portfolio company. The deal expands Recipharm's capabilities into viral vaccines, viral vectors and oncolytic virus manufacturing while Vibalogics will continue operating from its Boxborough, MA and Cuxhaven, Germany facilities.
-
Biogen Acquires Alcyone Therapeutics
September 19, 2025
Medical Devices
Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.
-
Cycle Pharmaceuticals (Cycle Group) Acquires Applied Therapeutics, Inc.
February 3, 2026
Pharmaceuticals
Cycle Group Holdings Limited (Cycle Pharmaceuticals) has completed the acquisition of NASDAQ-listed Applied Therapeutics, a clinical-stage biopharmaceutical company focused on novel CNS-penetrant therapies for rare metabolic diseases. The transaction was funded from Cycle's cash on hand and brings Applied's lead candidate govorestat and rare-disease pipeline into Cycle's rare metabolic disease platform.
-
Juvenescence Acquires AI Drug-Discovery Company Ro5
June 5, 2025
Biotechnology
Juvenescence Limited has acquired Ro5 Inc., an AI-driven drug discovery company, to integrate Ro5's Biomedical Knowledge Graph and AI chemistry platform into Juvenescence's R&D operations. The deal strengthens Juvenescence's machine-learning drug discovery capabilities and supports its strategic partnership with Abu Dhabi-based M42 to accelerate the development of therapeutics targeting age-related diseases.
-
Cytiva Acquires Vanrx Pharmasystems
February 1, 2021
Medical Devices
Cytiva has acquired Vanrx Pharmasystems, a Canadian maker of robotic aseptic filling machines, adding drug‑product filling capability to Cytiva’s bioprocessing portfolio. The deal brings Vanrx’s ~120 employees into Cytiva and expands Cytiva’s end‑to‑end “idea to injection” offering for biopharmaceutical manufacturers.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.